Εμφανίζονται 1 - 2 Αποτελέσματα από 2 για την αναζήτηση 'on behalf of the FUTURE 2 Study Group', χρόνος αναζήτησης: 0,03δλ Περιορισμός αποτελεσμάτων
  1. 1
    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study ανά Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group

    Έκδοση 2018-06-01
    Λήψη πλήρους κειμένου
    Άρθρο
  2. 2
    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... ανά L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group

    Έκδοση 2018-12-01
    Λήψη πλήρους κειμένου
    Άρθρο

Εργαλεία αναζήτησης: